三生制药
3SBIO INC.

2022年度业绩公告路演

2023年3月21日

免责声明

This document has been prepared by 3SBio Inc. (the "Company") solely for selected recipients for information purposes only.

You must read the terms, conditions, limitations, notifications, restrictions, acknowledgments and representations in the following (collectively, the "Terms") before reading or making any other use of this document. In accepting the delivery of, reading or making any other use of this document, you acknowledge and agree to be bound by the Terms, and you agree to maintain absolute confidentiality regarding the information disclosed in this document in a manner consistent with the Terms. If you do not accept any of the Terms, in whole or in part, please immediately return this document to the Company.

These materials, and any further information made available to you, are highly confidential and are being given solely for your information. These materials, and any further information made available to you, form part of the proprietary information of the Company and may not be copied, reproduced, redistributed or passed on, directly or indirectly, to any other person (whether within or outside your organization/firm) or published or otherwise disclosed, in whole or in part, in any manner and for any purpose without the prior written consent from the Company. Any forwarding, distribution or reproduction of this document, in whole or in part, is unauthorized.

The information used in preparing this document has not been independently verified and has not been reviewed by any regulatory authority in any jurisdiction. This document does not purport to provide a complete description of the matters to which it relates. No representation, warranty or undertaking, express or implied, is or will be made or given by, and no responsibility or liability is or will be accepted by, any person (for the avoidance of doubt, including but not limited to, the Company and its affiliates, controlling persons, shareholders, directors, officers, partners, employees, agents, representatives or advisers of any of the foregoing), with respect to the accuracy, reliability, correctness, fairness or completeness of this document or its contents or any oral or written communication in connection with this document. In addition, any analyses included herein are not and do not purport to be complete or comprehensive and are not and do not purport to be appraisals of the assets, stock or business of the Company or any of its holding companies, subsidiaries or other affiliates. Even when these materials contain a form of appraisal, it should be considered as preliminary, suitable only for the purpose described herein, subject to assumptions and not be disclosed or otherwise used without the prior written consent of the Company. The information in this document does not take into account the effects of a possible transaction or certain transactions which may have significant valuation and other effects. Nothing contained in this document is, or shall be, relied upon as a promise or representation as to the future or as a representation or warranty otherwise.

Nothing in this document constitutes or forms part of, or should be construed as constituting or forming part of, any regulatory, valuation, legal, tax, accounting, investment, or other advice. Nothing in this document constitutes or forms part of, or should be construed as constituting or forming part of, any recommendation, solicitation, offer or commitment to purchase, sell, subscribe for or underwrite any securities by any party, or to extend any credit or provide any insurance to you or to enter into any transaction, nor shall there be any sale of securities or other transaction in any jurisdiction in which such sale or transaction would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Unless otherwise agreed in writing, any third party from whom you receive this document is not acting as your financial adviser or fiduciary. Before you enter into any transaction, you should ensure that you fully understand the potential risks and rewards of that transaction and you should consult with such advisers as you deem necessary to assist you in making these determinations, including, but not limited to, your accountants, investment advisors and legal and/or tax experts. None of the Company and its affiliates, controlling persons, shareholders, directors, officers, partners, employees, agents, representatives or advisers of any of the foregoing shall have any liability (in negligence or otherwise) in respect of the use of, or reliance upon, the information contained herein by you or any person to whom the information herein is disclosed.

The contents of this document are subject to corrections or changes at any time without further notice. The information contained in these materials also contains certain forward-looking statements regarding the Company's intent, plans, beliefs, strategies, and growth prospects as well as the projected growth of China's economy and the pharmaceutical industry, which are based on various assumptions and subject to risks and uncertainties. In light of these assumptions, risks, and uncertainties, the future facts, events and circumstances described in these materials may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. The forward-looking statements are not guarantees of future performance. Each of the Company and its and its affiliates, controlling persons, shareholders, directors, officers, partners, employees, agents, representatives or advisers of any of the foregoing assumes no obligation to (1) provide access to any additional information, (2) correct any mistakes or inaccuracies in this document, or (3) update or otherwise revise this document, for any reason whatsoever, including without limitation to reflect new information, events or circumstances that arise, occur or become known after the date of this document.

By receiving or reading this document, you acknowledge and represent to the Company and its affiliates, controlling persons, shareholders, directors, officers, partners, employees, agents, representatives or advisors that (1) you are a "professional investor" as defined in the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and the rules made thereunder, have the knowledge and experience in financial and business matters, and are capable of evaluating the merits and risks of and conducting your own assessment of the Company and its shares, (2) you are a person into whose possession this document may lawfully be delivered in accordance with the laws of the jurisdiction in which you are located, and (3) you have conducted and will conduct your own investigation with respect to the Company and its shares and have obtained or will obtain your own independent advice relating to the investment in the shares of the Company, and, if located in the United States, are either a "qualified institutional buyer" or an institutional "accredited investor" as defined in the U.S. Securities Act of 1933, as amended, and the regulations enacted thereunder (the "U.S. Securities Act").

No information set out in this document will form the basis of or be relied upon in connection with any contract, commitment or investment decision. Any prospective investor will be required to acknowledge in any purchase contract that it has not relied on, or been induced to enter into such agreement by, any representation or warranty, save as expressly set out in such agreement. This document does not constitute, in whole or in part, an offer or invitation for the sale, purchase or subscription of any security. Any such offer or invitation will be made solely through a prospectus or offering circular in compliance with all applicable laws and any decision to purchase or subscribe for any security should be made solely on the basis of the information contained in such prospectus or offering circular issued in connection with such offer or invitation.

This document contains no information or material which may result in it being deemed (1) to be a prospectus within the meaning of the U.S. Securities Act; (2) to be a prospectus within the meaning of section 2(1) of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong), or an advertisement in relation to a prospectus or proposed prospectus or extract from or abridged version of a prospectus within the meaning of section 38B of the Companies (Winding Up and Miscellaneous Provisions) Ordinance or an advertisement, invitation or document containing an advertisement or invitation falling within the meaning of section 103 of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) or (3) to have effected an offer to the public in the United States, Hong Kong or anywhere else without compliance with all applicable laws and regulations or being able to invoke any exemption available under all applicable laws and regulations and is subject to material change without notice. The distribution of this document may be restricted by law, and persons into whose possession this document comes should inform themselves of, and observe, any such restrictions. Any failure to comply with these restrictions may constitute a violation of the applicable securities laws. The Company does not intend to conduct any public offering of securities in the United States, Hong Kong or anywhere else.

目录

01 业绩亮点

董事长兼首席执行官

娄竞 博士

2022年业绩摘要

营业收入



归母净利润



正常化归母净利润



每股收益



2022年四大业务领域

生物制药


特比澳®


益比奥® 赛博尔®


益赛普®


赛普汀®

核心品种收入**52.4**亿元，

同比增长**3.0%**

毛发健康


蔓迪


蔓迪小白瓶


蔓迪 Pro


蔓迪 洗发水

核心品种收入**9.1**亿元，

同比增长**46.5%**

CDMO

外部订单收入**1.7**亿元

同比增长**49.6%**

R&D


益赛普预充针


Remitch


蔓迪泡沫剂

4

个小分子递交ANDA

8个新药上市申报、受理中

31个管线产品

2022年主要里程碑

新药研发

重点品种向临床后期推进

2022.06 特比澳治疗慢性肝病患者血小板减少症的Ib／二期临床试验已完成

2022.08-12 抗IL-1β 单抗（613）治疗急性痛风关节炎Ib 期临床完成入组；抗IL-5 单抗（610）治疗嗜酸性粒细胞哮喘Ⅱ期临床入组启动；抗IL-4R 单抗（611）治疗特应性皮炎美国Ia期临床已完成，国内Ⅱ期临床入组即将完成

2022.11 特比澳儿童ITP适应症提交上市申请并获得受理

2022.11 抗IL-17A单抗（608）中重度斑块状银屑病Ⅱ期临床研究达到主要终点，Ⅲ期临床试验入组中

毛发健康

打造毛发健康第一品牌

2022.01 蔓迪5%米诺地尔泡沫剂上市申请获受理

2022.06 与Cosmo合作引入痤疮乳膏剂Winlevi® 大中华商业化权益和脱发用药Breezula®的优先购买权

2022.06 蔓迪“618”电商销售再创新高

2022.11 蔓迪位列2022年上半年中国网上药店药品终端化学药品牌排名第一，并获2022双十一阿里健康&京东健康药品单品冠军

生物制药

核心生物药受到更多指南认可

2022.04 赛普汀进入《乳腺癌诊疗指南（2022版）》抗HER2治疗的I级推荐用药

2022.04 特比澳纳入《CSCO肿瘤治疗所致血小板减少症诊疗指南（2022）》CTIT治疗一级推荐用药

2022.04 益比奥36000IU规格纳入《肿瘤相关性贫血实践指南2022》

CDMO

客户服务能力逐步提升

2022.06 助力客户产品成功递交BLA

2022.10 广东三生基地获得药品生产许可证

2022.12 沈阳德生基地获得药品生产许可证

ESG治理获MSCI AA评级

超过全球**88%**

的生物科技公司

使命

让创新生物药触手可及

愿景

立足中国，成为全球领先的生物制药公司

价值观

创新，质量，合作共赢

理念

珍爱生命， 关注生存，创造生活

社会责任

社会贡献

特比澳慈善捐赠
益赛普慈善捐赠
益赛普自主降价

环境保护

持续的能源节约
和气体减排

人才发展

人才培训、人才留存
和人才晋升体系



02 业绩概况

生物制药

特比澳—全球唯一商业化重组人血小板生成素

特比澳2022年销售收入

百万元

YOY：10.3%



1 市占率首位

以销售额计市占率**65%** [1]，继续居于升血小板药物市场首位



1.数据来源： IQVIA 2022年1-12月，市场总量包含重组人血小板生成素，白介素-11及泊帕类

特比澳-明确的作用机制带来显著的临床优势

更快速的起效时间，更高的安全性

结构与内源性TPO（eTPO）高度一致



- ✓ 氨基酸序列高度一致
- ✓ 糖基化修饰完整且接近
- ✓ 作用机理相同

700余篇研究文章，多次登上国际学术论坛

特比澳相比罗普司亭、艾曲泊帕的差异化信号通路

- 特比澳结合胞外C-MPL受体，同时激活JAK-STAT、MAPK、PI3K-AKT三条通道
- 相比小分子和罗普司亭，激活信号传导的强度更强



特比澳-持续拓展肿瘤TCP市场

肿瘤治疗所致血小板减少症（CTIT）

指肿瘤患者在疾病治疗过程中因**抗肿瘤治疗**导致的血小板减少症，

包括既往临床常见的**化疗**所致血小板减少症，

也包括**放疗**，**靶向治疗**和**免疫治疗**所致的血小板减少症[1]



化疗TCP患者

100+万患者群体，目前主要肿瘤适应症的覆盖领域，持续下沉



放疗TCP患者

30+万患者群体，PLT低于$75*10^9$则治疗中断率接近50%

手术TCP患者

20+万患者群体，创口较大手术的PLT阈值不得低于$100*10^9$

拓展适应症	研发进展
儿科ITP	NDA已获受理
慢性肝病血小板减少症	III期临床启动，拓展肝病人群空间
骨髓型急性放射病的紧急救治	动物模型验证有效性，作为骨髓型急性放射病紧急救治药物，单次大剂量已写入《职业性外照射急性放射病诊断》推荐治疗方法
多学科拓展	再生障碍性贫血，造血干细胞移植后促归巢，脓毒症相关血小板减少等

1. CSCO《肿瘤治疗所致血小板减少症诊疗指南 2022》

促红素-益比奥 & 赛博尔双品牌

促红素2022年销售收入

百万元

YOY：0.9%

1 市占率首位

两品种市占率**44.5%**，稳居EPO产品市占率第一



促红素-需求拉动持续增长

指南推荐增加，诊疗障碍解除，EPO临床需求持续提升

36% 透析贫血治疗渗透率[1]

10% 肿瘤贫血治渗透疗率

- 肾性贫血治疗血红蛋白质控标准提升[2]，用药需求进一步增加
- 诊疗指南增加EPO 在肿瘤相关性贫血领域的应用推荐[3]
- 诊疗活动恢复，手术用药等压制需求重回增长
- 80万+透析群体，10%年增长率，EPO在CKD贫血治疗上极具性价比

1.数据来源：CNRDS 2020
2.卫健委《2021年质控工作改进目标的函（国卫医质量便函[2021]51号）》
3.《肿瘤相关性贫血实践指南2022》增加36000IU EPO 对于MDS（骨髓异常增生综合征）的Ⅰ级推荐

益赛普-多维探索，积极应对变革

益赛普2022年销售收入



符合慢病治疗需求的首选生物制剂

18年中国患者临床应用经验印证

需求重回增长

慢病治疗需求重回正常

拓展新剂型

预充剂型预计3月上市；配注射套组的新包装已上市

开拓新合作

与中医风湿体系合作，立足联用疗法重磅询证证据，寻求新的渠道增长点

持续基层下沉

积极推动基药目录准入工作，大力推进乡村振兴项目，提高基层诊疗水平，巩固先入优势

中国第一个上市的TNF-α抑制剂 | 近18年临床使用经验 | 累计惠及患者超十万人 | 培训定点医院项目相关医务人员15012人 | 覆盖3700余家医疗机构，包括县级医院900多家

赛普汀-进入高速增长快车道

赛普汀2022年销售收入

百万元

YOY：138.1%



文件名称	发布单位	发布时间	调整内容
《乳腺癌诊疗指南》（2022年）	CSCO（中国临床肿瘤学会）	2022	晚期乳腺癌一线用药
《国家医保目录》2022年版	国家医保局	2023	解除长春瑞宾联用限制

	2021	2022
覆盖医疗机构	590	1300
覆盖患者总数	3000	10000
平均单月新患数	200	500
人均用药时长	2 个DOT[1]	~7个DOT

1. DOT（药物治疗持续时间） 赛普汀为21天

毛发健康

蔓迪-安全有效的外用脱发药物龙头

蔓迪2022年销售收入

百万元

1 **市占率首位**

蔓迪市占率**71.7%**，稳居米诺地尔市场第一[1]



1. 市占率数据来源：CPA

蔓迪-三大渠道推动快速增长

院线

14%收入占比， **2%**YOY

- 学术认可持续提升，获女性雄激素脱发（FAGA）指南最高等级推荐
- 布局民营连锁医疗机构专线渠道，扩大连锁机构合作规模

药店

25%收入占比， **65%**YOY

- 覆盖药店提升至10万家，百强连锁总部覆盖近90%

国大药房 GuoDa Pharmacy
益丰大药房 Yifeng Pharmacy
大参林 DA SHEN LIN
北京同仁堂
老百姓大药房 LBX PHARMACY
海王星辰 NEP-STAR DRUG STORE

电商

60%收入占比， **58%**YOY

- 线上年触达人群 2000万+，客户300万
- 新客占比~70%，客单价200+
- 女性用户占比持续上升

电商平台	排名	“双11”战报
天猫	1	OTC脱发销售榜首
京东	1	自营OTC皮肤用药第1
京东大药房	1	大药房单品排名第1

蔓迪-打造产品矩阵，开拓广阔市场



01 蔓迪

60/90mL 男士单月装/疗程装

02 蔓迪 小白瓶

30mL女性单月装，方便定量

03 蔓迪 泡沫剂

即将上市，填补头皮敏感人群用药需求

04 蔓迪 Pro 随身装

10mL小容量，配置多种刷头，满足出差，旅游场景便携需求

05 蔓迪 小密梳

兼具激光按摩和上液功能，上药、养护一体智能工具

06 蔓迪 洗发水

向毛发相关的生活场景渗透

CDMO

国内CDMO服务先行者

CDMO业务2022年收入

百万元

制剂	生物药	GCT	生物药




Sirton Pharmaceuticals　SIGO 晟国医药　广东三生 Guangdong Sunshine　德生生物 Desen Biologics

53%
海外子公司收入增长

43%
国内子公司收入增长

1
个商业化产品

100Mn+
在手订单总额

7.6 万升产能将陆续启用 承接商业化订单

产能建设持续推进

新增1200万支 制剂产能将于2022年Q4陆续投产完成将是目前产能4倍

粉针/冻干粉　西林瓶　预充针

一期工程2000L一次性原液线和4000万支制剂线已建设完成；二期培养基和填料项目开工

生物药　亲和层析填料　培养基　制剂

Sirton

广东三生

已于9月获得生产许可证，首个面向FDA市场的服务合同已经签订落地

生物药　基因与细胞治疗　制剂

德生生物

晟国医药

3500L 一次性发酵产能，预计23年Q2建设完成

生物药　制剂

03 新药研发

研发管线



4个
临床前产品

4个
IND&临床I期

8个
临床II期

10个
临床III期&NDA

5个
BE/ANDA产品

- 小分子药物
- 抗体药物
- 其他生物药

研发展望-即将迎来产品商业化热潮

NDA/ANDA审评中

预计上市时间 **2023**

赛博宁	安毕霉	Remitch	益赛普	蔓迪	特比澳	托法替布	碳酸司维拉姆
那曲肝素钙注射液	两性霉素B脂质体	盐酸纳呋拉啡口崩片	预充针	米诺地尔泡沫剂	儿童 ITP	原料药及片剂	片剂

提交/准备 BLA/ANDA

预计上市时间 **2024**

SSS06	SSS11	阿普斯特	盐酸西那卡塞	艾曲泊帕
长效EPO（双周制剂）	Pegsiticase 尿酸酶（US）	原料药及片剂	原料药及片剂	原料药及片剂

临床 III 期

预计NDA提交 **2024-2025**

TPO	601A(VEGF)	608(IL-17A)	RD01
CLDT	BRVO	银屑病	长效EPO（月制剂）

临床 II 期

HIF117	611	610	613
贫血	特应性皮炎	哮喘	急性痛风关节炎

临床 I 期和 IND 阶段

705	707	621	Remitch	SSS11
抗 PD1/HER2 双抗	抗 PD1/VEGF 双抗	COPD	肝病瘙痒	Pegsiticase 尿酸酶（中国）

8 个品种预计将于**2023**获批上市

管线重点品种-SSS06 (长效重组人红细胞生成素)

II期临床显示安全有效

- 二代 EPO, 半衰期延长，给药间隔可延长至两周，匹配化疗患者治疗周期
- II期数据显示两个剂量组均安全有效，用药后血红蛋白（Hb）变化与现有EPO产品基本一致
- 研发进展位列国内第二位，III期入组已完成

2024
预计NDA

rhEPO 和 SSS06 临床疗效数据对比：

	rhEPO（维持筛选剂量）	rESA QW（0.5ug/kg）	rESA QOW（1.0ug/kg）
平均基线血红蛋白(g/L)	110.70	110.1	**112.9**
评价期平均血红蛋白(g/L)	108.9	106.5	**107.7**
主要疗效终点			
评价期平均Hb相对基线变化(g/L)	-1.8	-3.7	**-5.1**
评价期平均Hb相较基线变化量修正均数(g/L)	-6.5	-8.3	**-8.2**
修正均数差值(95% CI)		1.8(-1.8, 5.4)	**1.6(-2.1, 5.4)**

管线重点品种-608（抗IL-17A 单抗）

PsO II期临床数据显示确切疗效

- 12周数据显示，608各剂量组疗效并明显优于安慰剂组及已上市品种，具备 **Best-In-Class 潜质**

	608A组 (n=28)	608B组 (n=31)	608C组 (n=35)	安慰剂 (n=11)	司库奇尤单抗 300mg (W0~W4 QW) + Q4W
PASI 75	96.4%	93.5%	100.0%	9.1%	80.6%
PASI 90	92.9%	83.9%	91.4%	0.0%	57.2%
PASI 100	46.4%	48.4%	57.1%	0.0%	33.6%
sPGA 0/1	89.3%	83.9%	91.4%	9.1%	67.9%
PASI 75 +sPGA 0/1	89.3%	83.9%	91.4%	9.1%	/
PASI 90 +sPGA 0/1	89.3%	80.6%	91.4%	0	/

- 研发进展位列国内**第三**位

2024 预计NDA

608、司库奇尤单抗、依奇珠单抗银屑病患者12周主要终点数据



注：T=试验药物，P=安慰剂组

1. 608 A组代表：160mg LD(loading dose)+80mg Q2W，608 B组代表：160mg Q2W；**608 C组代表**：160mg Q4W
2. PASI75, PASI90,PASI100分别定义为PASI较基线改善≥75%，≥90%和≥100%
3. sPGA 0/1定义为sPGA为0分或1分，且较基线降低≥2分；sPGA 0定义为银屑病皮损完全消退

管线重点品种-613 (抗IL1β 单抗)

有效的改善急性痛风性关节炎疼痛

- Ib期数据显示，613各剂量组均可看到急性痛风疼痛VAS评分较基线的明显改善

	100 mg (N=10)	200 mg (N=10)	300 mg (N=10)
基线	66.90 (13.195)	62.10 (10.311)	60.70 (13.475)
给药后6H相对基线变化（%）	-9.67 (11.941)	-18.93 (13.510)	-14.34 (17.445)
给药后24H相对基线变化（%）	-38.43 (34.236)	-45.20 (16.921)	-29.15 (29.012)
给药后72H相对基线变化（%）	**-56.91 (42.359)**	**-71.77 (27.254)**	**-62.50 (30.287)**
给药后D7相对基线变化（%）	-82.12 (20.480)	-78.96 (20.279)	-74.77 (16.228)
给药后D14相对基线变化（%）	-85.18 (19.638)	-89.37 (12.249)	-91.96 (11.265)
给药后D28相对基线变化（%）	**-85.49 (30.870)**	**-93.48 (9.202)**	**-90.85 (15.645)**

- 研发进展位列国内第二位：急性痛风性关节炎II期招募中；周期性发热综合征、全身型幼年特发性关节炎I期已完成

2025
预计NDA

目标关节VAS疼痛评分下降与卡纳单抗类似



管线重点品种-611 (抗-IL4R 单抗)

Ib数据显示611针对重度AD患者应答迅速

- 16周数据显示，611在中重度AD患者给药2周后即开始起效，应答迅速，疗效持续

	611 (NCT05641558)			
第16周疗效结果	300+150 QW (n=6)	600+300 Q2W (n=4) *	600+300 QW (n=6)	安慰剂组 (n=5)
EASI-75	83.3	50.0	66.7	0.0

- 611有高于Dupilumab相应指标应答率的趋势
- 研发进展位列国内第三位

2026 预计NDA



管线重点品种-610 (抗-IL5 单抗)

显著改善重度哮喘患者的肺功能

- 研发进展位列国内第一位

企业名称	产品代码	适应症
三生国健	SSGJ-610	嗜酸性粒细胞哮喘II期招募中
恒瑞医药	SHR-1703	嗜酸性粒细胞哮喘II期招募中；哮喘I期招募中；支气管哮喘I期已完成
百奥泰	美泊利珠单抗-BAT 2606	慢性鼻窦炎伴鼻息肉病I期招募完成

- 重度嗜酸性粒细胞哮喘患者的II期研究正在入组中

2026 预计NDA

Ib临床盲态下分析结果显示FEV1改善



三大双特异性抗体平台



- 可形成两条相同长重链和四条相同轻链组成的结构对称四价双特异性抗体
- 理化性质稳定，成药性媲美单抗
- 已开发超过8款双靶点的双抗组合

CLF2（common light chain Linear-Fabs-IgG）双抗平台



- 支持个性化设计生产单/多价双抗、三抗
- 稳定scFv、Linker设计避免错配，具有与单抗相似的稳定性和半衰期
- 大肠杆菌直接生产蛋白-毒素结构分子，渗透性高、药效强、成本显著降低

MAP（Multi-directional Association Platform ）双抗平台



- 独创的纳米抗体VHH / IgSF的双抗平台
- 对称结构，纯化工艺简单，表达量和稳定性与单抗相当

VRD-Body（Variable Regions Derivatives-Body）双抗平台

管线重点品种- Remitch

Remitch （盐酸纳呋拉啡口崩片）

日本肝肾疾病瘙痒指南一线用药

- 血透相关的尿毒症瘙痒（UP）-2009
- 慢性肝病相关瘙痒（CLD-aP）-2015
- 腹透相关瘙痒 -2017

Kappa阿片受体激动剂，避免呼吸抑制、 便秘和成瘾性

获批后将是国内首个治疗透析瘙痒的药物品种

2018 成功引进

2019 获批IND

2021 桥接临床成功

2022 提交NDA并获受理

独家品种，聚焦百万患者的未满足临床需求

01 **诊疗不规范**
缺乏诊疗指南，未能正确筛查、诊断与治疗

02 **疗效欠佳**
现有治疗手段无法提供一致的，充分的瘙痒缓解

03 **适应症空白**
国内无批准的治疗方案，现有药物多为超适应症使用

04 **副作用大**
瘙痒导致患者药物过度使用，合并感染、心血管事件等副作用，阿片类药物成瘾性高

05 **生存质量低**
60%睡眠障碍；抑郁可能性高2倍；整体死亡率增高24%

管线重点品种-Remitch

1

首个唯一对症药物

获批后将是国内首个且唯一具有透析瘙痒适应症治疗的药物品种，解决传统阿片类药物呼吸抑制、 便秘和成瘾性

透析瘙痒



透析瘙痒目标人群

>30w

- 国内百万透析群体中**80%**的患者伴随不同程度的瘙痒
- 约有**42%**的中重度瘙痒无法得到有效缓解

肝病瘙痒



肝病瘙痒目标人群

>100w

- 不同肝病种类中，瘙痒发病率为5%-70%
- 肝病瘙痒的患者中超过**57%**对现有治疗无效



国际化合作-License in

克拉考特酮（WS204）

1st in Class 的AR靶点痤疮治疗用药

- 2022年7月，三生制药与Cosmo公司合作引入痤疮治疗用药Winlevi®（克拉考特酮1%乳膏剂）大中华商业化权益
- 以及治疗脱发的Breezula®（克拉考特酮7.5%溶液剂）的优先购买权（2022.07）

Winlevi® (clascoterone) cream 1%

1st

美国40年来批准的首个新机制痤疮治疗用药

- Winlevi®是Cosmo 开发的全球**首款**上市的针对12岁以及上的寻常痤疮患者的**外用雄激素受体抑制剂**，于2021年11月获得FDA批准上市[1]

45万

美国处方量最大的痤疮用药

- Winlevi®已经成为美国市场处方量**最大**的痤疮药物，截至2022年末，有超过1万名的医生开具了该款药品的处方，处方量超45万张[2]

创新治疗品种，开发中国市场巨大潜力

以上中国人有不同程度的痤疮问题[2]

年龄介于10至25岁的年轻群体有寻常痤疮

的比例出现痤疮瘢痕，对患者的生理和心理造成损害



1：www.winlevi.com

2：www.cosmopharma.com, Bloomberg

国际化合作-License out

SSS11 Pegsiticase

PEG修饰的重组尿酸酶

- 产出于产朊假丝酵母
相比于其他尿酸酶在人体生理性PH值上具备更高活性

609A

重组人源化抗PD-1抗体

- 用于特定联合疗法（肿瘤免疫疗法syncrovax）的全球权益授权给美国Syncromune公司，公司将获得总计数亿美金的首付款+里程碑付款+其他激励

赛普汀

伊尼妥单抗

- 赛普汀用于抗体偶联药物（ADC）开发和商业化的全球权益授权科岭源，交易总金额最高可至10.25亿人民币

2014	2020.07	2020.11	2022	2023Est.
达成合作	深入合作	达成里程碑	CDMO	BLA to FDA
3SBio 将Pegsiticase的权益(除大中华区和日本以外) 授予 **Selecta** 用作fSEL-212的组合疗法, SEL-212包括pegsiticase和ImmTOR®免疫耐受平台	**Sobi** 和 **Selecta**宣布，两家公司已就Selecta研发产品SEL -212达成了战略许可协议 **Sobi**负责大中华区以外所有市场的开发、注册和商业活动，而Selecta则代表Sobi开展第III期研究	Selecta已代表Sobi™开展组合疗法SEL-212用于慢性难治性痛风的第**III期**临床试验，并向三生制药支付**400万美元**的里程碑付款	3SBio 向 Selecta/Sobi提供尿酸酶原液 **21** 批， 准备 **PPQ**批次药品原液供应	3SBio 将收到**里程碑付款**，持续的 **销售分成** 以及药品原液供应的 **CDMO 收入**

三生制药 3SBIO INC. Selecta Biosciences sobi

04 财务回顾

财务分析

营业收入



毛利



母公司拥有人应占纯利



同口径调整后正常化归母净利润



费用管理

销售费用



销售费用率	36.9%	36.7%	36.1%	36.4%	37.6%

研发费用



研发费用率	7.9%	9.9%	10.6%	11.8%	10.1%

管理费用



管理费用率	6.9%	12.7%	8.1%	5.8%	5.6%

总资产负债

总资产



净资产



资产负债率



现金流情况优秀，现金资产储备充裕

经营性现金流



现金资金（含理财）



收益具有显著吸引力

每股收益（元）



ROE



持续稳健增长，坚持股东回馈

归属股东净利润
5年CAGR 10.7%

业绩稳健

持续向股东交付稳健增长的业绩

SUSTAINABLE

特比澳

独家品种

顺利续约，增长潜力可期

EXCLUSIVE

赛普汀

一线用药

临床认可提升，打开增长瓶颈，步入全面增长

PROFESSIONAL

蔓迪

第一品牌

渗透率提升，高增长持续，皮肤毛发领域不断拓展

UNIQUE

研发

新药上市

2023年起即将迎来超过10款[1]新药陆续上市

PROMISING

分红派息
稳健的盈利水平支持**可持续**的派息政策

股票回购
回购5% 股份，缓解股东压力

CB 回购
回购 可转债 **3000万** 欧元，增强CB稳定性，提振投资者信心

股本注销
注销 **3.4%** 的股本，增厚EPS，增加股权价值，回报长期股东

1：预计将包括Remitch，益赛普预充针，蔓迪泡沫剂，特比澳儿科ITP，托法替布片，碳酸司维拉姆片，阿普斯特片，盐酸西那卡塞片，艾曲泊帕片，抗IL-17抗体等

05 问答环节

THANKS

3SBio Inc. (1530.HK)
Investor Relations
ir@3sbio.com

珍 爱 生 命 · 关 注 生 存 · 创 造 生 活

CHERISH LIFE CARE FOR LIFE CREATE LIFE